49 142

Cited 0 times in

Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer

Authors
 Hye Yeon Yang  ;  Min Yu Kang  ;  Chang Moo Kang  ;  Woo Jung Lee  ;  Ho Kyoung Hwang 
Citation
 YONSEI MEDICAL JOURNAL, Vol.65(6) : 324-331, 2024-06 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2024-06
MeSH
Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors / therapeutic use ; Carcinoma, Pancreatic Ductal* / drug therapy ; Carcinoma, Pancreatic Ductal* / mortality ; Carcinoma, Pancreatic Ductal* / pathology ; Carcinoma, Pancreatic Ductal* / surgery ; Disease-Free Survival ; Female ; Humans ; Hypertension / drug therapy ; Male ; Middle Aged ; Pancreatic Neoplasms* / drug therapy ; Pancreatic Neoplasms* / mortality ; Pancreatic Neoplasms* / pathology ; Pancreatic Neoplasms* / surgery ; Retrospective Studies
Keywords
Angiotensin system inhibitor ; ductal adenocarcinoma ; pancreatic cancer ; survival
Abstract
Purpose: The microenvironment of pancreatic ductal adenocarcinoma (PDAC) with extensive desmoplastic stroma contributes to aggressive cancer behavior. Angiotensin system inhibitors (ASIs) reduce stromal fibrosis and are a promising therapeutic strategy. The purpose of this study was to examine how ASIs affected the oncological results of patients who had their PDAC removed.

Materials and Methods: A retrospective assessment was conducted on the clinicopathological and survival data of patients who received curative resection for PDAC at Severance Hospital between January 2012 and December 2019.

Results: A total of 410 participants (228 male and 182 female), with a median follow-up period of 12.8 months, were included in this study. Patients were divided into three groups, based on ASI use and history of hypertension: group 1, normotensive and never used ASI (n=210, 51.2%); group 2, ASI non-users with hypertension (n=50, 12.2%); and group 3, ASI users with hypertension (n=150, 36.6%). The three groups did not differ significantly in terms of age, sex, kind of operation, T and N stages, or adjuvant and neoadjuvant therapy. Moreover, there was no discernible difference in disease-free survival between those who used ASI and those who did not (p=0.636). The 5-year overall survival (OS) rates in groups 1, 2, and 3 were 52.6%, 32.3%, and 38.0%, respectively. However, the OS rate of ASI users was remarkably higher than that of non-users (p=0.016).

Conclusion: In patients with resected PDAC, ASI is linked to longer survival rates. Furthermore, for individuals with hypertension, ASI in conjunction with conventional chemotherapy may be an easy and successful treatment option.
Files in This Item:
T202403247.pdf Download
DOI
10.3349/ymj.2023.0399
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Minyu(강민유)
Kang, Chang Moo(강창무) ORCID logo https://orcid.org/0000-0002-5382-4658
Yang, Hye Yeon(양혜연) ORCID logo https://orcid.org/0000-0002-7831-2341
Lee, Woo Jung(이우정) ORCID logo https://orcid.org/0000-0001-9273-261X
Hwang, Ho Kyoung(황호경) ORCID logo https://orcid.org/0000-0003-4064-7776
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/199825
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links